BMHS Development Tracks for 2022

Bundamedik Tbk, or BMHS, targets revenue growth of up to 30% in 2023. In 2022, the company targets an increase of 23% from last year's revenue or the equivalent of an EBITDA of IDR 350 billion.

Managing Director Nurhadi Yudiyantho said that in the first half of 2022, the company had reached an EBITDA of IDR 169 billion. This figure can still grow by 10% in the second semester compared to the previous year.

Until the end of the year, it is estimated to reach IDR 350 billion for EBITDA. Meanwhile, for the following year, namely 2023, the company hopes that revenue can increase by 20-30% compared to this year.

Also Read: First 1000 Days of Birth with Bunda Group Hospital

BMHS Goals for 2023

The 2022 achievement, which is estimated to be up to Rp. 350 billion is measured based on the company's EBITDA margin footprint, where the margin as a company profit still occurs at 23% until the first semester of 2022.

The consistent increase in the margin of 1% every year indicates that the target set by the company can be estimated easily. The achievement itself has been carried out through various strategies.

PT Bundamedik Tbk has an integrated and leading service health ecosystem in Indonesia. The company focuses on three strategic pillars to drive sustainable business growth throughout 2022. The three pillars are ecosystem expansion, core business strengthening, and strategic partnership deepening.

Through the three pillars of the priority strategy, BMHS targets non-Covid revenue growth of 20% -30% and EBITDA growth of 1% annually. On an ongoing basis, the target for the coming year will be easily achieved.

From the first pillar, strengthening the core business, the company focuses on transforming the customer journey, namely the experience of patients getting health services according to their needs. This is supported by good digital services, using the ehealth.bunda.co.id application.

An omnichannel approach is also carried out by bringing together efficient, seamless, and paperless offline and online services. These three will become service transformation priorities in the next phase.

Other strategies are collaborating with academic institutions, increasing medical partners, and increasing the standardization of acquisition hospitals. From the acquisition strategy, BMHS has contributed Rp 318 billion in CAPEX absorption for purchasing new hospitals and medical equipment.

In 2022 the company acquired 3 new hospitals, RSU Citra Harapan Bekasi, RSJP Paramarta, and RSIA Pusura Tegal Sari Surabaya, as a form of expansion included in the agenda for achieving the 2022 target and in the coming years.

Also Read: RSIA Pusura Tegalsari, the Surabaya Expansion of Morula Indonesia

BMHS Persists on Serve The Best

The manager of Bunda Hospital PT Bundamedik Tbk recorded the addition of four hospitals in six months in 2022 - RSIA Azzahra Palembang, RSIA Pusura Tegalsari Surabaya, RSU Citra Harapan Bekasi, and RSJP Paramarta Bandung.

From these additions, Bundamedik has become an integrated ecosystem covering 9 Bunda Group Hospitals, 10 Morula IVF clinics, 126 fertility satellite clinics of the Indonesian Fertility Clinic, 40 Pathology Laboratories, and Genomic Diagnostics.

BMHS also has more than 150 primary service clinic networks, Smart Clinic, ER Medical Evacuation team, and IMTB medical tourism services that reach more people in various regions of the country.

According to its Main Director, Mesha Rizal Sini, the BMHS expansion target has been fulfilled in six months. Meanwhile, Morula IVF and Diagnos will continue with expansion plans for the remainder of 2022.

A significant increase in the number of hospitals has occurred, along with an increase in non-COVID patients who have returned to using treatment and care facilities in hospitals, especially elective surgery.

The number of inpatients and outpatients increased by 42% and 12% (YoY), respectively. For elective surgery patients, growth was recorded to increase by 41%. In proportion to the increase in the number of hospitals, the change in beds also increased by 54%, from 414 to 639 in the same period this year.

Compared to the pre-pandemic period (2019), the Morula cycle was recorded to have increased by 28%. The number of cycles outside Jakarta continues to increase by 22% (YoY). This reflects the promising potential to meet the increasing demand for IVF services in metropolitan cities outside Java.

The existence of the Diagnos Laboratory grew almost 2-fold to reach 40 outlets, with a significant increase in tests outside of COVID-19. As of 1H2022, non-COVID lab test results increased by 19% YoY. During this period, BMHS maintained an increase in non-COVID revenue of 9% (YoY).

Compared to the pre-pandemic period, in semester 1 of 2019, the company's consolidated revenue during semester 1 of 2022 was recorded to have increased by 55%. EBITDA margin for H1 2022 rose 1 point to 18% (YoY).

Compared to Net Income (minus doctor's medical services), the EBITDA Margin is 23% during semester 1 of 2022. This is the company's preference for realizing sustainable core business development.

The company has been in the healthcare sector for 49 years and has always put forward a sustainable business growth strategy. Its development in 2022 motivates BMHS to present leading and reliable standardization of quality health services for the community.

Also Read: One Bunda: BMHS Digital Health Integration for Quality and Modern Services

Read more about BMHS developments here and their CSR activities here. You can also read BHMS asset information here.

Reviewed by:

dr. Harmeni Wijaya, M.D
Corporate Communications
PT Bundamedik Tbk